TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9684909

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (120 mg ZnSO4 after each dialysis session)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (Group II)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy subjects (HS) (Group III)
Number of subjects: 26
Study: 7851362

Group type: EXPERIMENTAL
Intervention: HIGH-FAT diet (70% fat, 7% CHO)
Number of subjects: 5

Group type: COMPARATOR
Intervention: HIGH-CHO diet (74% CHO, 12% fat)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: HIGH-FAT diet
Number of subjects: 5

Group type: COMPARATOR
Intervention: HIGH-CHO diet
Number of subjects: 5
Study: 2670447

Group type: EXPERIMENTAL
Intervention: 5000 IU of heparin (subcutaneously, twice daily) for 14 to 21 days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group without anticoagulant prophylaxis
Number of subjects: 103
Study: 1158003

Group type: EXPERIMENTAL
Intervention: 5% nickel sulfate and 0.1% triamcinolone acetonide in petrolatum
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5% nickel sulfate in petrolatum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide infiltration
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution infiltration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide cream
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cream base alone
Number of subjects: 15
Study: 31226684

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA) using Prestige LP Cervical Disc
Number of subjects: 209

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA)
Number of subjects: 209
Study: 29157765

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (CHD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 5% glucose intravenous infusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fasting from midnight
Number of subjects: 90
Study: 25951426

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% cream
Number of subjects: 41
Study: 23731186

Group type: EXPERIMENTAL
Intervention: Respondent-driven sampling (RDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General practice (GP) recruitment
Number of subjects: 0
Study: 21219504

Group type: EXPERIMENTAL
Intervention: Oral swab test
Number of subjects: 32

Group type: COMPARATOR
Intervention: Blood test
Number of subjects: 32
Study: 20035588

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 16275661

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 266

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 266
Study: 12421482

Group type: EXPERIMENTAL
Intervention: Pollen extract EA-10, P5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10530656

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 91

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 91
Study: 7854376

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg per day)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Clotrimazole troches (10 mg taken five times daily)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Fluconazole and Clotrimazole
Number of subjects: 428
Study: 1941832

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a dosage of 0.15‐0.2 mg/kg/day (9 mg/day maximum)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 88
Study: 7048825

Group type: EXPERIMENTAL
Intervention: Proximate stapler
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional skin closure
Number of subjects: 137
Study: 6704012

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgically treated eyes
Number of subjects: 0
Study: 30082137

Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy with autotransplantation of 45 fragments
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy with autotransplantation of 90 fragments
Number of subjects: 69
Study: 26851189

Group type: EXPERIMENTAL
Intervention: Handheld lights (with or without polarizing filter)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Viewing booth
Number of subjects: 96

Group type: COMPARATOR
Intervention: Before sessions using viewing booth
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: After sessions using handheld lights
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Education and training
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined effect of light and education/training
Number of subjects: 96
Study: 24769601

Group type: EXPERIMENTAL
Intervention: Korean Immigrants and Mammography‐Culture‐Specific Health Intervention (KIM‐CHI) program (n = 211 couples)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Attention control group (n = 217 couples)
Number of subjects: 428
Study: 22549295

Group type: EXPERIMENTAL
Intervention: PEA-based optimization of CRT
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (standard methods)
Number of subjects: 268
Study: 19736051

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol and simethicone solution (2l) 16h before VCE
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fibre-free diet and clear liquids the day before VCE
Number of subjects: 60
Study: 18569948

Group type: EXPERIMENTAL
Intervention: Amiodarone prophylaxis
Number of subjects: 0
Study: 15793647

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation
Number of subjects: 4
Study: 12090863

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 10628058

Group type: EXPERIMENTAL
Intervention: Health checks
Number of subjects: 1371
Study: 8750399

Group type: EXPERIMENTAL
Intervention: Intramuscular meloxicam (15 mg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Oral meloxicam (15 mg)
Number of subjects: 113
Study: 2040038

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (120 mg i.v. repeated after 4 hours) + metoclopramide (0.5 mg/kg i.v. bolus over 30 min + 1 mg/kg continuous infusion over 24 h) + alprazolam (0.5 mg p.o.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional antiemetic regimen (metoclopramide + alprazolam) without high-dose methylprednisolone
Number of subjects: 30
Study: 6452794

Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg b.i.d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desipramine 75 mg b.i.d.
Number of subjects: 40
Study: 31107793

Group type: EXPERIMENTAL
Intervention: Behavioral feeding intervention (n=12)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 29071370

Group type: EXPERIMENTAL
Intervention: 0.5% hypobaric bupivacaine USpA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% hypobaric ropivacaine USpA
Number of subjects: 60
Study: 24915175

Group type: EXPERIMENTAL
Intervention: Saffron (300 mg/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg, 25 mg thrice a day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 39
Study: 23809501

Group type: EXPERIMENTAL
Intervention: GnRH antagonist initiation on cycle day 2
Number of subjects: 160

Group type: COMPARATOR
Intervention: GnRH antagonist initiation on cycle day 6 (control)
Number of subjects: 160
Study: 21070806

Group type: EXPERIMENTAL
Intervention: Moderate‐to‐vigorous intensity aerobic exercise 45 min/day, 5 days/week for 1 year
Number of subjects: 320

Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 320
Study: 19898206

Group type: EXPERIMENTAL
Intervention: Delayed tacrolimus with basiliximab and mycophenolate mofetil (Tac‐d)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard tacrolimus with mycophenolate mofetil and steroids until day 91 (Tac‐s)
Number of subjects: 254
Study: 18085138

Group type: EXPERIMENTAL
Intervention: Integration treatment group (AMIE methods: acupuncture, massage, injection, and animal exercise therapies)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rehabilitation group (Bobath training therapy)
Number of subjects: 120
Study: 14967451

Group type: EXPERIMENTAL
Intervention: EGFR inhibitors (monoclonal antibodies and small molecular weight compounds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies with EGFR inhibitors
Number of subjects: 0
Study: 12588463

Group type: EXPERIMENTAL
Intervention: Glucagon (4.8 microg kg(‐1) bolus followed by 9.6 microg kg(‐1) h(‐1) infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 10948696

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.396 microgram administered intravenously as a bolus injection)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High urine flow rate (indicating overhydration)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indirect-response model
Number of subjects: 8
Study: 7744168

Group type: EXPERIMENTAL
Intervention: High spatial uncertainty
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low spatial uncertainty
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High event rate with high spatial uncertainty
Number of subjects: 72
Study: 1787707

Group type: EXPERIMENTAL
Intervention: Thermal application for a week
Number of subjects: 7

Group type: COMPARATOR
Intervention: No thermal application for a week (Control)
Number of subjects: 7
Study: 6957155

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clofibrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30707138

Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 29185878

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST) for 6 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care treatment
Number of subjects: 33
Study: 27004462

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (NC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No active treatment (noNC)
Number of subjects: 0
Study: 25391355

Group type: EXPERIMENTAL
Intervention: Echocardiography-guided (EG) lead placement strategy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Routine lead placement strategy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Patients with QRS > 150 ms
Number of subjects: 183
Study: 22943446

Group type: EXPERIMENTAL
Intervention: Bilaminar technique (BT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laterally moved, coronally advanced flap (LMCAF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both BT and LMCAF
Number of subjects: 50
Study: 20439345

Group type: EXPERIMENTAL
Intervention: Liposomal cisplatin (200 mg/m²) and paclitaxel (135 mg/m²)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m²) and paclitaxel (135 mg/m²)
Number of subjects: 236
Study: 17673811

Group type: EXPERIMENTAL
Intervention: ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 40
Study: 15620492

Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous electrical nerve stimulation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11893434

Group type: EXPERIMENTAL
Intervention: Massage therapy by mothers
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Massage therapy by trained professionals
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 57
Study: 9689902

Group type: EXPERIMENTAL
Intervention: Vitamin D administration in addition to Rifampicin, Isoniazid and Streptomycin (Group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rifampicin, Isoniazid and Streptomycin (Group A)
Number of subjects: 24
Study: 8210015

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 2573240

Group type: EXPERIMENTAL
Intervention: Melperone (300 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Melperone
Number of subjects: 20
Study: 4214889

Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine postoperative irradiation therapy
Number of subjects: 0
Study: 31814307

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20
Study: 29982728

Group type: EXPERIMENTAL
Intervention: Flavored waterpipe tobacco
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-flavored waterpipe tobacco
Number of subjects: 32
Study: 28590834

Group type: EXPERIMENTAL
Intervention: Pharm Booklet
Number of subjects: 402

Group type: COMPARATOR
Intervention: LONG DA
Number of subjects: 402

Group type: COMPARATOR
Intervention: SHORT DA
Number of subjects: 402

Group type: COMPARATOR
Intervention: LONG DA or SHORT DA
Number of subjects: 402
Study: 25040553

Group type: EXPERIMENTAL
Intervention: nCPAP treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 140
Study: 23477366

Group type: EXPERIMENTAL
Intervention: Task-specific training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study: 21496468

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18516713

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17296461

Group type: EXPERIMENTAL
Intervention: Tramadol 37.5-mg/acetaminophen 325-mg combination tablets (tramadol/APAP)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 14521597

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg alternate daily
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg day-1
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg day-1
Number of subjects: 91
Study: 11135129

Group type: EXPERIMENTAL
Intervention: Falls and mobility intervention featuring preventive home visits by public health nurses
Number of subjects: 0
Study: 9104905

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: Anticoagulant monotherapy
Number of subjects: 6797
Study: 7962319

Group type: EXPERIMENTAL
Intervention: DHEAS levels measured 3 times at 6-month intervals in group 1 (elderly women)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: DHEAS levels measured 6 times over 2 consecutive weeks in group 2 (healthy men)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cortisol levels measured concomitantly in both groups
Number of subjects: 57
Study: 2442543

Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg b.i.d. on a low sodium diet (50 mmol sodium/24 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg b.i.d. on a liberal sodium diet (200 mmol sodium/24 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enalapril, 10 mg b.i.d. on both diets
Number of subjects: 10
Study: 31420190

Group type: EXPERIMENTAL
Intervention: PCOS pharmaceutical care service (verbal and written educational materials focusing on diet and exercise)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard counseling (control group)
Number of subjects: 118
Study: 29557402

Group type: EXPERIMENTAL
Intervention: Curvomax abutment
Number of subjects: 49

Group type: COMPARATOR
Intervention: GingiHue abutment
Number of subjects: 49
Study: 27321596

Group type: EXPERIMENTAL
Intervention: Pentraxin 3 (PTX3)
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 1315
Study: 26348782

Group type: EXPERIMENTAL
Intervention: Forced-air warming blanket
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heated overblanket (Control)
Number of subjects: 40
Study: 24087999

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (60 mg/day for 8 weeks)
Number of subjects: 0
Study: 21816033

Group type: EXPERIMENTAL
Intervention: Home-based prevention program 'In control: No alcohol!' consisting of five printed magazines and an activity book
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving a factsheet information brochure (standard alcohol brochure of the Trimbos Institute)
Number of subjects: 0
Study: 19114142

Group type: EXPERIMENTAL
Intervention: Exercise program (12 weeks, 3 sessions of 60 min per week)
Number of subjects: 32
Study: 16111790

Group type: EXPERIMENTAL
Intervention: High dose of live attenuated oral monovalent G1 human rotavirus vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low dose of live attenuated oral monovalent G1 human rotavirus vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine childhood vaccines
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both dosages of HRV vaccine
Number of subjects: 100
Study: 15130227

Group type: EXPERIMENTAL
Intervention: Early liver retraction
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Delayed liver retraction
Number of subjects: 12
Study: 10960940

Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative gemcitabine/cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 9308065

Group type: EXPERIMENTAL
Intervention: Chloral hydrate and promethazine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 42
Study: 8285331

Group type: EXPERIMENTAL
Intervention: Split laryngeal mask airway
Number of subjects: 30

Group type: COMPARATOR
Intervention: Berman II airway
Number of subjects: 30
Study: 3577278

Group type: EXPERIMENTAL
Intervention: 4 g Mezlocillin (Baypen) i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 60
Study: 29290380

Group type: COMPARATOR
Intervention: Postoperative IV fluids at the surgeon's discretion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No postoperative IV fluids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (IV fluids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study group (no IV fluids)
Number of subjects: 0
Study: 26549222

Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: OrthoMTA
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ERRM
Number of subjects: 104

Group type: COMPARATOR
Intervention: Blood contamination
Number of subjects: 104

Group type: COMPARATOR
Intervention: Saline contamination
Number of subjects: 104
Study: 23873670

Group type: EXPERIMENTAL
Intervention: ONO‐5334 50 mg twice daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: ONO‐5334 100 mg once daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: ONO‐5334 300 mg once daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: Alendronate 70 mg once weekly
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 22269729

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 82

Group type: COMPARATOR
Intervention: Bone wax
Number of subjects: 82
Study: 19762071

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 260

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 260
Study: 17684522

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (Vitamin A-deficient placebo group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (Vitamin A-sufficient placebo group)
Number of subjects: 70
Study: 15968885

Group type: COMPARATOR
Intervention: Single dose of S-3304 (10 - 800 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Multiple dose of S-3304 (200 mg, 400 mg, 800 mg b.i.d.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Multiple dose of S-3304 (800 mg b.i.d.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single dose of S-3304 (800 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single dose of S-3304 (high-fat diet effect)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Multiple doses of S-3304
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: S-3304 (800 mg b.i.d.)
Number of subjects: 48
Study: 14629247

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ergotamine tartrate 2 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11307227

Group type: EXPERIMENTAL
Intervention: Rigid and wire fixation (intervention group)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Post-Surgical Patient Satisfaction Questionnaire (PSPSQ)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Oral Health Status Questionnaire (OHSQ)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Eysenck Personality Inventory (EPI), Sickness Impact Profile (SIP), Revised Symptom Checklist‐90 (SCL‐90‐R)
Number of subjects: 117
Study: 8885732

Group type: EXPERIMENTAL
Intervention: Terbutaline 5 mg orally every 4 hours
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Magnesium chloride 128 mg orally every 4 hours
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: All groups (Placebo, Terbutaline, Magnesium)
Number of subjects: 205